Isolated hyperkalemia associated with cyclosporine administration in allogeneic stem cell transplantation for renal cell carcinoma.

Abstract

Two patients with advanced renal cell carcinoma underwent allogeneic hematopoietic stem cell transplantation and received cyclosporine (CSP) as part of their immunosuppressive therapy. Despite adequate renal function, both patients developed hyperkalemia. CSP was the only pharmaceutical agent to which this electrolyte abnormality could be attributed. Evaluation of renal tubule function suggested that CSP-associated isolated hyperkalemia resulted from tubular resistance to aldosterone. We propose that the presence of a single functional kidney may be a risk factor for isolated hyperkalemia due to CSP.

• Authors: Akiyoshi Takami, Hidesaku Asakura, Hiroyuki Takamatsu, Hirohito Yamazaki, Masahisa Arahata, Tomoe Hayashi, Masami Shibayama, Michiko Orito, Tomotaka Yoshida, Mikio Namiki, Shinji Nakao
• Journal: International journal of hematology (Int J Hematol) Vol. 81 Issue 2 Pg. 159-61 (Feb 2005) ISSN: 0925-5710 [Print] Japan
• PMID: 15765786 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cyclosporine

Topics

• Adult
• Carcinoma, Renal Cell (complications, therapy)
• Cyclosporine (adverse effects)
• Hematopoietic Stem Cell Transplantation (adverse effects, methods)
• Humans
• Hyperkalemia (chemically induced)
• Kidney Tubules (drug effects)
• Male
• Middle Aged
• Transplantation, Homologous